Recombinant Rhesus Macaque Fms-related Tyrosine Kinase 3 Ligand
Flt-3 ligand (FL) is a recently identified hematopoietic cytokine whose activities are mediated by binding to the transmembrane glycoprotein Flt-3. Flt-3 was first discovered as a member of the class III subfamily of receptor tyrosine kinases (RTK) whose expression among hematopoietic cells was found to be restricted to highly enriched stem/progenitor cell populations. Additionally, class III RTKs include the receptors from SCF, M-CSF and PDGF. Not surprisingly, Flt-3 ligand is also structurally related to M-CSF and SCF. All three cytokines have been shown to exist both as type I transmembrane proteins and as soluble proteins. The predominant human FL isoform is a transmembrane protein that can undergo proteolytic cleavage to generate a soluble form of the protein. FL has been shown to synergize with a wide variety of hematopoietic cytokines to stimulate the growth and differentiation of early hematopoietic progenitors.
Reference
1. Hacein-Bey S, Basile GD, Lemerle J, et al. 1998. Blood, 92: 4090-7
2. Peters M, Solem F, Goldschmidt J, et al. 2001. Exp Hematol, 29: 146-55
3. Beq S, Fontanet A, Theze J, et al. 2004. AIDS, 18: 2089-91
4. Mahadevan D, Choi J, Cooke L, et al. 2009. Hum Genomics Proteomics, 2009: 453634
5. Coates PT, Barratt-Boyes SM, Zhang L, et al. 2003. Blood, 102: 2513-2
1.
| Gene ID | 719239 |
| Accession # | H9Z6V7 |
| Alternate Names | Flt3L, SL cytokine |
| Source | Escherichia coli. |
| M.Wt | Approximately 18.0 kDa, a single non-glycosylated polypeptide chain containing 159 amino acids. |
| AA Sequence | TQDCSFQHSP ISSDFAVKIR ELSDYLLQDY PVTVPSNLQD EELCGALWRL VLAQRWMERL KTVAGSKMQG LLERVNTEIH FVTKCAFQHP PSCLRFVQTN ISRLLQETSE QLVALKPWIT RQNFSRCLEL QCQPDSSTLP PPRSPGALEA TALTAPQRP |
| Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. - 12 months from date of receipt, -20 to -70 °C as supplied. - 1 month, 2 to 8 °C under sterile conditions after reconstitution. - 3 months, -20 to -70 °C under sterile conditions after reconstitution. |
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4. |
| Reconstitution | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Biological Activity | Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using human AML5 cells is less than 1.0 ng/ml, corresponding to a specific activity of > 1.0 × 106 IU/mg. |
| Shipping Condition | Gel pack. |
| Handling | Centrifuge the vial prior to opening. |
| Usage | For Research Use Only! Not to be used in humans. |
Quality Control & DataSheet
- View current batch:
-
Purity > 97 % by SDS-PAGE and HPLC analyses.
- Datasheet
Endotoxin: Less than 1 EU/μg of rRhFlt-3L as determined by LAL method.